Stock Financial Ratios, Dividends, Split History

KONA / Kona Grill, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)30.49
Enterprise Value ($M)69.47
Book Value ($M)3.17
Book Value / Share0.24
Price / Book1.07
NCAV ($M)-76.59
NCAV / Share-5.78
Price / NCAV-0.39
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 10,121,000
Common Stock Shares Outstanding 10,109,715
Weighted Average Number Of Diluted Shares Outstanding 10,121,000
Common Shares Outstanding 10,109,715
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.53
Return on Assets (ROA)-0.22
Return on Equity (ROE)-0.74
Balance Sheet (mrq) ($M)
Quick Ratio0.30
Current Ratio0.39
Income Statement (mra) ($M)
Food And Beverage Revenue0.00
Operating Income-21.09
Net Income-23.43
Earnings Per Share Diluted-2.32
Earnings Per Share Basic-2.32
Earnings Per Share Basic And Diluted-2.32
Cash Flow Statement (mra) ($M)
Cash From Operations5.90
Cash from Investing-11.71
Cash from Financing-11.71
Identifiers and Descriptors
Central Index Key (CIK)1265572
Related CUSIPS
50047H951 50047H901

Split History

Stock splits are used by Kona Grill, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Kona Grill's (KONA) CEO Berke Bakay on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon and thank you for joining us today to discuss Kona Grill's results for the First Quarter Ended March 31, 2018. With us are Berke Bakay, Kona Grill's President and Chief Executive Officer; and Christi Hing, Chief Financial Officer. Following their remarks, we'll open the call for your questions. [Operator Instructions] (4-0)

Kona Grill: Turnaround Unlikely

2018-05-09 seekingalpha
Kona's top line is showing deceleration, growing only 5% y/y in 2017 vs. their ~20% CAGR from 2013-2016. (4-1)

BRIEF-Kona Grill Appoints Alex Zheng To Board Of Directors As Vice Chairman

2018-05-02 reuters

Competition And Creditors Squeezing Kona Grill Simultaneously

2018-03-23 seekingalpha
Shares of 1-rated Kona Grill (KONA) are sinking below $2 per share today after reporting fourth quarter same-store sales declines of 6.5%, which ranks among the worst in the dining sector. The company has hired a new COO recently to try and improve the business' performance on both the sales and profit margin lines, but external factors will make it hard for KONA to compete. (4-1)

Kona Grill's (KONA) CEO Berke Bakay on Q4 2017 Results - Earnings Call Transcript

2018-03-23 seekingalpha
Good afternoon, and thank you for joining us today to discuss Kona Grill's results for the fourth quarter ended December 31, 2017. With us are Berke Bakay, Kona Grill's President and Chief Executive Officer; and Christi Hing, Chief Financial Officer. Following their remarks, we'll open up the call for your questions. [Operator Instructions]. (5-1)

CUSIP: 50047H201